Biogen’s controversial Alzheimer’s drug aducanumab — which goes before an FDA Advisory Committee panel this week — should not be approved because it failed to show efficacy, said Mayo Clinic’s David Knopman, MD, who was involved in one of the aducanumab trials, and others, in Alzheimer’s & Dementia.
Cleveland Clinic researchers did not agree, saying “lack of approval would be devastating not only to patients who will lose hope but advocates and the community at large.” (Alzheimer’s & Dementia)
A novel investigational PET tracer, 18F-PM-PBB3, captured abnormal tau protein deposits in Alzheimer’s disease and frontotemporal lobar degeneration disorders with high contrast. (Neuron)
Undiagnosed, untreated sleep disorders were tied to physician burnout. (JAMA Network Open)
No significant association was found between multiple sclerosis and vitiligo, a review concluded. (Nature Scientific Reports)
The Stentrode, an endovascular motor neuroprosthesis implanted via a jugular vein, helped two severely paralyzed patients with amyotrophic lateral sclerosis (ALS) send text messages, shop online, and manage finances through direct thought. (Journal of NeuroInterventional Surgery)
Do some people infected with COVID-19 have a higher risk of Parkinson’s disease? Three case reports suggest it might be so. (Trends in Neurosciences)
Whether migraine patients have a higher risk for symptomatic COVID-19 due to shared comorbidities was reviewed. (Headache)
The Nerivio neuromodulation device now has an expanded indication for chronic migraine, device maker Theranica announced.
Long-term exposure to community noise was associated with higher risk of mild cognitive impairment and Alzheimer’s disease and worse cognitive performance, specifically in perceptual speed, in older adults. (Alzheimer’s & Dementia)